Figure 6
Combined effect of hPUMA and cisplatin on two xenograft models: tumor suppression and survival advantage in mice. A2780s cells (A, C) or SKOV3 cells (B, D) of 2 × 106 were inoculated subcutaneously into female nude mice at 6–8 wks of age. Mice (five per group) were treated with PBS, pc3.1, hPUMA, Cis and hPUMA + Cis. In an A2780s tumor model, significant differences in tumor suppression (**P < 0.001) and survival time (ΔP < 0.05) in mice treated with hPUMA or cisplatin versus PBS and pcDNA3.1 controls are shown. Also shown are the significant difference for tumors treated with hPUMA + cisplatin versus PBS and pcDNA3.1 controls (**P < 0.001; ΔΔP < 0.01) and the significant difference for the combination therapy versus hPUMA or cisplatin monotherapy (#P < 0.05; $P < 0.05). Similar results were also found in the SKOV3 model, except that no significant differences in tumor suppression (P = 0.262) and survival time (P = 0.634) between cisplatin- and pcDNA3.1-treated tumors were found.